Complement receptor type 1 (CRI, CD35) is a membrane glycoprotein that is present on erythrocytes, leukocytes, glomerular podocytes, and splenic follicular dendritic cells, and mediates the binding by these cells of particles and immune complexes that have activated complement (1, 2) . This function of CRl is dependent on its capacity to bind reversibly the C3b and C4b fragments of C3 and C4 that are covalently attached to activators of complement . CRl also can inhibit complement activation by impairing the formation and function ofthe alternative and classical pathway C3/C5 convertases, and by serving as a cofactor for the cleavage by factor I of C3b to iC3b, C3c and C3d,g, and of C4b to C4c and C4d.Four molecular weight allotypes of CRl have been described that vary by increments of 40,000-50,000, and each is able to mediate binding ofC3b (1, 3). The most frequently occurring F or A allotype has an Mr after reduction of 250,000 on SDS-PAGE. The receptor is comprised ofa single polypeptide chain and has an estimated six to eight N-linked complex oligosaccharides and no 0-linked carbohydrate. The amino acid sequence of -75% of the extracellular region, the single 25-amino acid membrane spanning domain, and the 43-amino acid cytoplasmic sequence has been determined by sequence analysis of overlapping cDNA clones (4). The extracellular domain consists of a series of tandemly arranged short consensus repeats (SCRs)' of 60-70 amino acids, each SCR having four conserved cysteines and a consensus sequence involving -40% of the residues . Every eighth SCR is a highly homologous repeat, such that SCR 2, etc. are 65-100% identical . Thus, seven SCRs constitute a long homologous repeat (LHR). This earlier study presented the sequence of three LHRs, and a fourth NH2-terminal LHR was predicted for the F allotype (4).Although the LHR appears to be unique to CRl, the basic SCR structural element has been found in other C3/C4-binding proteins such as factor H, C4b-binding